Patients with early Alzheimer’s disease (AD) who initiated lecanemab treatment at a specialty memory clinic showed an expected and manageable side-effect profile, new research showed.
“The findings are very reassuring,” Barbara Joy Snider, MD, PhD, professor of neurology, and director of the Memory Diagnostic Center and Knight ADRC Clinical Trials Unit, Washington University School of Medicine, St. Louis, Missouri, told Medscape Medical News.
“We found similar rates of side effects in our patient population as were found in the phase 3 studies of lecanemab. Clinical trial volunteer participants tend to be very healthy, so it is not always a given that side effects will be similar in the clinical population, especially in older adults,” Snider explained.
The study was published online on May 12 in JAMA…